BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20464842)

  • 1. Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.
    Love RR
    Oncology (Williston Park); 2010 Apr; 24(4):322-7. PubMed ID: 20464842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant endocrine therapy for premenopausal women with breast cancer.
    Puhalla S; Brufsky A; Davidson N
    Breast; 2009 Oct; 18 Suppl 3(0 3):S122-30. PubMed ID: 19914530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Bao T; Davidson NE
    Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer.
    Rossi L; Pagani O
    J Womens Health (Larchmt); 2018 Apr; 27(4):466-475. PubMed ID: 28926289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F
    BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
    Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
    J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LHRH-agonist versus chemotherapy in premenopausal breast cancer?
    Klijn JG
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S45-6. PubMed ID: 12409071
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
    ; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
    Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meeting highlights: International consensus panel on the treatment of primary breast cancer.
    Love RR
    J Clin Oncol; 2002 Apr; 20(7):1955-6; author reply 1956-7. PubMed ID: 11919263
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
    Hubalek M; Brantner C; Marth C
    Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.